Vaccine development is not an all-or-nothing endeavor. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful.
News & Analysis: Inovio Pharmaceuticals
Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?
The biotech stock has been a winner so far this year. But can Inovio's momentum continue?
This story has a long way to go before being over.
Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.
With so many companies trying to solve the coronavirus problem, now's a critical time for the biotech stock.
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”
Shares of the COVID-19 vaccine developer have been on fire in 2020. ,
Is now a good time to get in on this biotech stock?
Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.